相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
Tatsunori Suzuki et al.
CANCER GENE THERAPY (2022)
Post-translational modification of KRAS: potential targets for cancer therapy
Wei-hua Wang et al.
ACTA PHARMACOLOGICA SINICA (2021)
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Chen Liu et al.
CLINICAL CANCER RESEARCH (2021)
The type of KRAS mutation drives PI3Kα/γ signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients
Coralie Cayron et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2021)
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Carmine Fedele et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann et al.
CANCER DISCOVERY (2021)
KRAS drives immune evasion in a genetic model of pancreatic cancer
Irene Ischenko et al.
NATURE COMMUNICATIONS (2021)
Searching for treatments for non-G12C-KRAS mutant cancers
Christina Guo et al.
BRITISH JOURNAL OF CANCER (2021)
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
David M. Briere et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka et al.
CANCER DISCOVERY (2021)
Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression
Chika Iwamoto et al.
CANCER LETTERS (2021)
Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
D. Lucas Kerr et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines
Laia Gorchs et al.
CANCERS (2021)
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Samuel A. Kerk et al.
NATURE REVIEWS CANCER (2021)
Tumor restriction by type I collagen opposes tumor- promoting effects of cancer-associated fibroblasts
Sonakshi Bhattacharjee et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Meagan B. Ryan et al.
CLINICAL CANCER RESEARCH (2020)
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
G. Aaron Hobbs et al.
CANCER DISCOVERY (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Misako Nagasaka et al.
CANCER TREATMENT REVIEWS (2020)
Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment
Prasenjit Dey et al.
CANCER DISCOVERY (2020)
Targeting the MAPK Pathway in KRAS-Driven Tumors
Matthias Drosten et al.
CANCER CELL (2020)
Computational Prediction and Validation of Tumor-Associated Neoantigens
Vladimir Roudko et al.
FRONTIERS IN IMMUNOLOGY (2020)
Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
Zhidong Wang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Jay B. Fell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Immunotherapy for pancreatic cancer: A 2020 update
Dimitrios Schizas et al.
CANCER TREATMENT REVIEWS (2020)
Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
Michael J. Bond et al.
ACS CENTRAL SCIENCE (2020)
Discovery of Novel PDEd Degraders for the Treatment of KRAS Mutant Colorectal Cancer
Junfei Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
Gal Cafri et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
Matthew J. LaMarche et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Ziyang Zhang et al.
ACS CENTRAL SCIENCE (2020)
Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo
Kotaro Sakamoto et al.
SCIENTIFIC REPORTS (2020)
Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer
Wells S. Brown et al.
CELL REPORTS MEDICINE (2020)
Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer
Robert S. Banh et al.
CELL (2020)
Immune modulatory effects of oncogenic KRAS in cancer
Shaima'a Hamarsheh et al.
NATURE COMMUNICATIONS (2020)
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Christina Guo et al.
LANCET ONCOLOGY (2020)
Trends in the Incidence of Pancreatic Adenocarcinoma in All 50 United States Examined Through an Age-Period-Cohort Analysis
Wilson L. da Costa et al.
JNCI CANCER SPECTRUM (2020)
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj et al.
NATURE REVIEWS CANCER (2020)
Ras-Mediated Activation of the Raf Family K nases
Elizabeth M. Terrell et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)
Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer
Christopher J. Halbrook et al.
CELL METABOLISM (2019)
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Roman C. Hillig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Understanding Cell Penetration of Cyclic Peptides
Patrick G. Dougherty et al.
CHEMICAL REVIEWS (2019)
The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer
Yuanliang Yan et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer
Yuanyuan Pei et al.
SMALL (2019)
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer A Phase 2 Randomized Clinical Trial
Thomas B. Karasic et al.
JAMA ONCOLOGY (2019)
Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors
Aslamuzzaman Kazi et al.
CLINICAL CANCER RESEARCH (2019)
Development of targeted protein degradation therapeutics
Philip P. Chamberlain et al.
NATURE CHEMICAL BIOLOGY (2019)
KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer
Emanuela Pupo et al.
FRONTIERS IN ONCOLOGY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Cancer Neoantigens
Ton N. Schumacher et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 37, 2019 (2019)
Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment
Ning Pu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo
Imran Khan et al.
ONCOGENE (2019)
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
Tamer A. Ahmed et al.
CELL REPORTS (2019)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Dietrich A. Ruess et al.
NATURE MEDICINE (2018)
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
Zhi Rong Qian et al.
JAMA ONCOLOGY (2018)
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
Robert J. Nichols et al.
NATURE CELL BIOLOGY (2018)
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
Carmine Fedele et al.
CANCER DISCOVERY (2018)
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
Andrew McGuigan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells
Pan-Yu Chen et al.
CANCER RESEARCH (2018)
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions
Paul A. Jackson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Inhibition of RAS function through targeting an allosteric regulatory site
Russell Spencer-Smith et al.
NATURE CHEMICAL BIOLOGY (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models
Katharina M. Schmidt et al.
ONCOTARGET (2017)
Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity
Matthias P. Mueller et al.
SCIENTIFIC REPORTS (2017)
Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer
Panagiotis Samaras et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
David R. Driscoll et al.
CANCER RESEARCH (2016)
Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
Christopher J. Tape et al.
CELL (2016)
The Significance of Ras Activity in Pancreatic Cancer Initiation
Craig D. Logsdon et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2016)
How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Ethan J. Brock et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)
Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion
Cristovao M. Sousa et al.
NATURE (2016)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Jonathan M. L. Ostrem et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sos1 disruption impairs cellular proliferation and viability through an increase in mitochondrial oxidative stress in primary MEFs
P. Liceras-Boillos et al.
ONCOGENE (2016)
KRAS-related proteins in pancreatic cancer
Karen M. Mann et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism
Hongyun Zhao et al.
ELIFE (2016)
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
Barbara Bournet et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Ras activation revisited: role of GEF and GAP systems
Anne Hennig et al.
BIOLOGICAL CHEMISTRY (2015)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Allelic Ratio of KRAS Mutations in Pancreatic Cancer
J. K. Lennerz et al.
ONCOLOGIST (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz et al.
NATURE COMMUNICATIONS (2015)
Ral small GTPase signaling and oncogenesis: More than just 15 minutes of fame
Leanna R. Gentry et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Andrew D. Rhim et al.
CANCER CELL (2014)
Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
Mara H. Sherman et al.
CELL (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Oncogenic K-Ras requires activation for enhanced activity
H. Huang et al.
ONCOGENE (2014)
Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma
Brian M. Wolpin et al.
ONCOLOGIST (2014)
The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells
Makoto Wada et al.
PLOS ONE (2014)
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Michael C. Burns et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity
Shao TengFei et al.
SCIENCE CHINA-LIFE SCIENCES (2014)
BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells By Reactivating MEK and ERK Signaling
Berta Sanchez-Laorden et al.
SCIENCE SIGNALING (2014)
KRAS: feeding pancreatic cancer proliferation
Kirsten L. Bryant et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
Dosage-Dependent Regulation of Pancreatic Cancer Growth and Angiogenesis by Hedgehog Signaling
Esha Mathew et al.
CELL REPORTS (2014)
Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
Nobuya Ishii et al.
CANCER RESEARCH (2013)
Targeting the RAS oncogene
Asami Takashima et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
Takeshi Ogura et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Metabolic Alterations in Lung Cancer-Associated Fibroblasts Correlated with Increased Glycolytic Metabolism of the Tumor
Virendra K. Chaudhri et al.
MOLECULAR CANCER RESEARCH (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
X. Sui et al.
CELL DEATH & DISEASE (2013)
Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression
Paolo Cirri et al.
CANCER AND METASTASIS REVIEWS (2012)
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
Carolina Navas et al.
CANCER CELL (2012)
EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
Christine M. Ardito et al.
CANCER CELL (2012)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan et al.
CLINICAL CANCER RESEARCH (2012)
Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia
Mitsuro Kanda et al.
GASTROENTEROLOGY (2012)
An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice
Jaroslaw Daniluk et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Meredith A. Collins et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Terence M. Williams et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins
Anchal Chandra et al.
NATURE CELL BIOLOGY (2012)
Regulating the regulator: post-translational modification of RAS
Ian M. Ahearn et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
Meredith A. Collins et al.
PLOS ONE (2012)
Pancreatic cancers require autophagy for tumor growth
Shenghong Yang et al.
GENES & DEVELOPMENT (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Targeting protein prenylation for cancer therapy
Norbert Berndt et al.
NATURE REVIEWS CANCER (2011)
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Milind M. Javle et al.
BMC CANCER (2010)
PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
Ensar Halilovic et al.
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Overexpression of Smoothened Activates the Sonic Hedgehog Signaling Pathway in Pancreatic Cancer-Associated Fibroblasts
Kimberly Walter et al.
CLINICAL CANCER RESEARCH (2010)
Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
Edoardo Missiaglia et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
Hua Tian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
Marie Dance et al.
CELLULAR SIGNALLING (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
GEFs and GAPs: Critical elements in the control of small G proteins
Johannes L. Bos et al.
CELL (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Farnesyl transferase inhibitors
AD Basso et al.
JOURNAL OF LIPID RESEARCH (2006)
Trp53R172H and KraSG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
SR Hingorani et al.
CANCER CELL (2005)
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer
S Rao et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
AJ Aguirre et al.
GENES & DEVELOPMENT (2003)
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
SR Hingorani et al.
CANCER CELL (2003)
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
SP Thayer et al.
NATURE (2003)
分享论文
